- Report
- October 2025
- 192 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- October 2025
- 187 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 188 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 195 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 187 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 189 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 184 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 186 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 193 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 191 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 189 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 187 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 199 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 185 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 193 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 183 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 188 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 180 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 197 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- August 2025
- 188 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP

The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more